Esperion Therapeutics, Inc. Initiates First HDL Therapy Clinical Trial / ApoA-I Milano Enters Human Trials

Ann Arbor, Mich. (ots-PRNewswire) - Esperion Therapeutics, Inc., (Nasdaq: ESPR), a biopharmaceutical company focused on discovering and developing HDL-targeted therapies for the treatment of cardiovascular and metabolic diseases, today announced the initiation of a phase I clinical trial of ApoA-I Milano (AIM). The phase I trial will include evaluation of the safety of AIM. AIM is a variant of ApoA-I (the major HDL protein) that is believed to protect against vascular disease by extracting cholesterol from the artery wall and transporting it to the liver for removal. The clinical use of AIM is as human recombinant protein complexed to phospholipid to mimic HDL function. AIM is present in a small population of Northern Italians with paradoxically low levels of HDL-cholesterol. Low HDL-cholesterol levels normally would correlate with high risk for cardiovascular disease, but people with AIM show a reduced risk. The clinical testing of AIM is a first for a human recombinant variant protein as a possible therapeutic agent.

Esperion Therapeutics

Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway. The RLT pathway is responsible for removing excess cholesterol from arteries and other tissues and for its transport to the liver for elimination from the body. The goal of Esperion is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has five product candidates under development for the treatment of cardiovascular and metabolic diseases. Esperion successfully completed an initial public offering on August 9, 2000, and is listed on the Nasdaq National Market under the symbol "ESPR."

Safe Harbor Statement

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These include statements regarding the progress of Esperion's products in development. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties that may cause actual results, performance or achievements, or industry results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. These include, for example, risks associated with the development of Esperion's product candidates, including regulatory approval, market acceptance, the Company's dependence on clinical research organizations, license arrangements and other strategic relationships, the Company's dependence on patents and proprietary rights, the Company's procurement, maintenance, enforcement and defense of its patents and proprietary rights, and risks related to manufacturing and the Company's ability to obtain additional financing on acceptable terms. These risks and uncertainties and other risks and factors are more fully described in the Company's Form S-1 Registration Statement. You should not place undue reliance on the Company's forward-looking statements. The Company does not intend to update any of these factors or to publicly announce the results of any revisions to any of these forward-looking statements.

Web site:

ots Original Text Service: Esperion Therapeutics, Inc.

Roger S. Newton, Ph.D.,
President and Chief Executive Officer, or
Timothy M. Mayleben,
Vice President, Finance and Chief Financial Officer, +1-734-332-0506,
both of Esperion Therapeutics, Inc.; or
Jacqueline Franchetti of JFCI,
for Esperion Therapeutics, Inc.

Web site: